ABSTRACT
The liver is the largest solid organ and is affected by many neoplastic and non-neoplastic pathological processes. Computed tomography (CT) is one of the most frequently used methods for the radiological evaluation of these processes. Understanding the lesion enhancement dynamics and designing the imaging protocol accordingly is necessary for characterizing neoplastic lesions. In this context, this review discusses imaging protocols in liver CT imaging, key insights into the characterization of the most common neoplastic lesions of the liver, and the applications of dual-energy CT in liver imaging.
Keywords:
Multidetector computed tomography, hepatocellular carcinoma, dual energy computed tomography
References
1
Lorente S, Hautefeuille M, Sanchez-Cedillo A. The liver, a functionalized vascular structure. Sci Rep. 2020; 10: 16194.
2
Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018; 289: 816-30.
3
Francis IR, Cohan RH, McNulty NJ, Platt JF, Korobkin M, Gebremariam A, et al. Multidetector CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. AJR Am J Roentgenol. 2003; 180: 1217-24. Erratum in: AJR Am J Roentgenol. 2003; 181: 283.
4
Johnson PT, Fishman EK. Routine use of precontrast and delayed acquisitions in abdominal CT: time for change. Abdom Imaging. 2013; 38: 215-23.
5
Monzawa S, Ichikawa T, Nakajima H, Kitanaka Y, Omata K, Araki T. Dynamic CT for detecting small hepatocellular carcinoma: usefulness of delayed phase imaging. AJR Am J Roentgenol. 2007; 188: 147-53.
6
Kartalis N, Brehmer K, Loizou L. Multi-detector CT: liver protocol and recent developments. Eur J Radiol. 2017; 97: 101-9.
7
Kulkarni NM, Fung A, Kambadakone AR, Yeh BM. Computed tomography techniques, protocols, advancements, and future directions in liver diseases. Magn Reson Imaging Clin N Am. 2021; 29: 305-20.
8
Schima W, Hammerstingl R, Catalano C, Marti-Bonmati L, Rummeny EJ, Montero FT, et al. Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: effect of contrast material flow rate. AJR Am J Roentgenol. 2006; 186: 1571-9.
9
Liver Imaging Reporting and Data System. ACR. Available from:
10
Cogley JR, Miller FH. MR imaging of benign focal liver lesions. Radiol Clin North Am. 2014; 52: 657-82.
11
Mamone G, Di Piazza A, Carollo V, Cannataci C, Cortis K, Bartolotta TV, et al. Imaging of hepatic hemangioma: from A to Z. Abdom Radiol (NY). 2020; 45: 672-91.
12
Caseiro-Alves F, Brito J, Araujo AE, Belo-Soares P, Rodrigues H, Cipriano A, et al. Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis. Eur Radiol. 2007; 17: 1544-54.
13
Reguram R, Ghonge A, Tse J, Dhanasekaran R. Practical approach to diagnose and manage benign liver masses. Hepatol Commun. 2024; 8: e0560.
14
Di Carlo I, Koshy R, Al Mudares S, Ardiri A, Bertino G, Toro A. Giant cavernous liver hemangiomas: is it the time to change the size categories? Hepatobiliary Pancreat Dis Int. 2016; 15: 21-9.
15
Gaa J, Saini S, Ferrucci JT. Perfusion characteristics of hepatic cavernous hemangioma using intravenous CT angiography (IVCTA). Eur J Radiol. 1991; 12: 228-33.
16
van Leeuwen MS, Noordzij J, Feldberg MA, Hennipman AH, Doornewaard H. Focal liver lesions: characterization with triphasic spiral CT. Radiology. 1996; 201: 327-36.
17
Leslie DF, Johnson CD, Johnson CM, Ilstrup DM, Harmsen WS. Distinction between cavernous hemangiomas of the liver and hepatic metastases on CT: value of contrast enhancement patterns. AJR Am J Roentgenol. 1995; 164: 625-9.
18
Kim T, Federle MP, Baron RL, Peterson MS, Kawamori Y. Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT. Radiology. 2001; 219: 699-706.
19
Oto A, Kulkarni K, Nishikawa R, Baron RL. Contrast enhancement of hepatic hemangiomas on multiphase MDCT: can we diagnose hepatic hemangiomas by comparing enhancement with blood pool? AJR Am J Roentgenol. 2010; 195: 381-6.
20
Alturkistany S, Jang HJ, Yu H, Lee KH, Kim TK. Fading hepatic hemangiomas on multiphasic CT. Abdom Imaging. 2012; 37: 775-80.
21
Dane B, Shanbhogue K, Menias CO, Taffel MT. The humbling hemangioma: uncommon CT and MRI imaging features and mimickers of hepatic hemangiomas. Clin Imaging. 2021; 74: 55-63.
22
Nguyen BN, Fléjou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol. 1999; 23: 1441-54.
23
Mortelé KJ, Praet M, Van Vlierberghe H, Kunnen M, Ros PR. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. AJR Am J Roentgenol. 2000; 175: 687-92.
24
Venkatesh SK, Chandan V, Roberts LR. Liver masses: a clinical, radiologic, and pathologic perspective. Clin Gastroenterol Hepatol. 2014; 12: 1414-29.
25
LeGout JD, Bolan CW, Bowman AW, Caserta MP, Chen FK, Cox KL, et al. Focal nodular hyperplasia and focal nodular hyperplasia-like lesions. Radiographics. 2022; 42: 1043-61.
26
Carlson SK, Johnson CD, Bender CE, Welch TJ. CT of focal nodular hyperplasia of the liver. AJR Am J Roentgenol. 2000; 174: 705-12.
27
Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007; 46: 740-8.
28
Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017; 152: 880-94.e6.
29
Dharmana H, Saravana-Bawan S, Girgis S, Low G. Hepatocellular adenoma: imaging review of the various molecular subtypes. Clin Radiol. 2017; 72: 276-85.
30
Tse JR, Felker ER, Naini BV, Shen L, Shen J, Lu DSK, et al. Hepatocellular adenomas: molecular basis and multimodality imaging update. Radiographics. 2023; 43: e220134.
31
Kahraman G, Haberal KM, Dilek ON. Imaging features and management of focal liver lesions. World J Radiol. 2024; 16: 139-67.
32
Alkofer B, Lepennec V, Chiche L. Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg. 2011; 148: 3-11.
33
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. Erratum in: J Hepatol. 2019; 70: 817.
34
Hariharan T, Mohammad H, Huay WY, Aher KB, Bhavar GB, Asane GS. Hepatocellular carcinoma imaging: exploring traditional techniques and emerging innovations for early intervention. Med Novel Technol Devices. 2024; 24: 100327.
35
Narsinh KH, Cui J, Papadatos D, Sirlin CB, Santillan CS. Hepatocarcinogenesis and LI-RADS. Abdom Radiol (NY). 2018; 43: 158-68.
36
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006; 6: 674-87.
37
Schwartz JNM, Carithers RL, Sirlin CB. Clinical features and diagnosis of hepatocellular carcinoma - 2023. UpToDate (serial online) May 20, 2025 (cited Jan 2026).
38
Mohnasky M, Gad S, Moon A, Barritt AS, Charalel RA, Eckblad C, et al. Hepatocellular carcinoma screening: from current standard of care to future directions. J Am Coll Radiol. 2025; 22: 260-8.
39
Mähringer-Kunz A, Steinle V, Düber C, Weinmann A, Koch S, Schmidtmann I, et al. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: the more, the worse? Liver Int. 2019; 39: 324-31.
40
Cannella R, Taibbi A, Porrello G, Dioguardi Burgio M, Cabibbo G, Bartolotta TV. Hepatocellular carcinoma with macrovascular invasion: multimodality imaging features for the diagnosis. Diagn Interv Radiol. 2020; 26: 531-40.
41
Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019; 39: 19-31.
42
Kovač JD, Janković A, Đikić-Rom A, Grubor N, Antić A, Dugalić V. Imaging spectrum of intrahepatic mass-forming cholangiocarcinoma and its mimickers: how to differentiate them using MRI. Curr Oncol. 2022; 29: 698-723.
43
Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017; 6: 22-34.
44
Chung YE, Kim MJ, Park YN, Choi JY, Pyo JY, Kim YC, et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics. 2009; 29: 683-700.
45
Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi L, Gusani NJ, et al. Epidemiology of liver metastases. Cancer Epidemiol. 2020; 67: 101760.
46
Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D’Angelica MI, Endo I, et al. Liver metastases. Nat Rev Dis Primers. 2021; 7: 27.
47
Gore RM, Thakrar KH, Wenzke DR, Newmark GM, Mehta UK, Berlin JW. That liver lesion on MDCT in the oncology patient: is it important? Cancer Imaging. 2012; 12: 373-84.
48
Freitas PS, Janicas C, Veiga J, Matos AP, Herédia V, Ramalho M. Imaging evaluation of the liver in oncology patients: a comparison of techniques. World J Hepatol. 2021; 13: 1936-55.
49
Lincke T, Zech CJ. Liver metastases: detection and staging. Eur J Radiol. 2017; 97: 76-82.
50
Ozaki K, Higuchi S, Kimura H, Gabata T. Liver metastases: correlation between imaging features and pathomolecular environments. Radiographics. 2022; 42: 1994-2013.
51
Rajesh S, Bansal K, Sureka B, Patidar Y, Bihari C, Arora A. The imaging conundrum of hepatic lymphoma revisited. Insights Imaging. 2015; 6: 679-92.
52
Salles-Silva E, de Castro PL, Ambrozino LC, de Araújo AL, Lahan-Martins D, Almeida MFA, et al. Rare malignant liver tumors: current insights and imaging challenges. Semin Ultrasound CT MR. 2025; 46: 161-76.
53
Stanietzky N, Salem AE, Elsayes KM, Rezvani M, Palmquist S, Ahmed I, et al. Unusual liver tumors: spectrum of imaging findings with pathologic correlation. Diagn Interv Radiol. 2025; 31: 58-67.
54
McCollough CH, Leng S, Yu L, Fletcher JG. Dual- and multi-energy CT: principles, technical approaches, and clinical applications. Radiology. 2015; 276: 637-53.
55
Marin D, Boll DT, Mileto A, Nelson RC. State of the art: dual-energy CT of the abdomen. Radiology. 2014; 271: 327-42.
56
Jing M, Sun J, Xi H, Liu Z, Zhang S, Deng L, et al. Abdominal virtual non-contrast images derived from energy spectrum CT to evaluate chemotherapy-related fatty liver disease. Quant Imaging Med Surg. 2023; 13: 669-81.
57
Shuman WP, Green DE, Busey JM, Mitsumori LM, Choi E, Koprowicz KM, et al. Dual-energy liver CT: effect of monochromatic imaging on lesion detection, conspicuity, and contrast-to-noise ratio of hypervascular lesions on late arterial phase. AJR Am J Roentgenol. 2014; 203: 601-6.
58
Okada H, Matsunaga N, Yamamoto T, Yamauchi M, Suzuki K. Evaluation of virtual monochromatic imaging with dual-energy computed tomography of small liver metastases from malignant abdominal tumours: quantitative and qualitative analyses. Acta Radiol Open. 2023; 12: 20584601231220324.
59
Kawano Y, Tanabe M, Higashi M, Kiyoyama H, Kamamura N, Ishii J, et al. Three-dimensional volumetric iodine mapping of the liver segment derived from contrast-enhanced dual-energy CT for the assessment of hepatic cirrhosis. Tomography. 2025; 11: 109.
60
Laroia ST, Bhadoria AS, Venigalla Y, Chibber GK, Bihari C, Rastogi A, et al. Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute. Eur J Radiol Open. 2016; 3: 162-71.
61
Ascenti G, Sofia C, Mazziotti S, Silipigni S, D’Angelo T, Pergolizzi S, et al. Dual-energy CT with iodine quantification in distinguishing between bland and neoplastic portal vein thrombosis in patients with hepatocellular carcinoma. Clin Radiol. 2016; 71: 938.e1-9.
